Adcetris brentuximab vedotin regulatory update

Seattle Genetics disclosed in its 4Q13 earnings that FDA granted Orphan Drug designation for Adcetris brentuximab vedotin to treat diffuse large B cell lymphoma (DLBCL). The product has Orphan Drug status in the U.S. and EU for Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). Adcetris also has Orphan Drug designation in the U.S. to treat angioimmunoblastic T cell lymphoma; mycosis fungoides, a type of cutaneous T cell lymphoma (CTCL); and peripheral T cell lymphoma (PTCL) that is not otherwise specified. In the EU, the product has Orphan Drug designation for CTCL. ...